瑞司美替罗
 | |
| 法律规范状态 | |
|---|---|
| 法律规范 |
|
| 识别信息 | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C17H12Cl2N6O4 |
| 摩尔质量 | 435.22 g·mol−1 |
| 3D模型（JSmol） | |
| |
瑞司美替罗（Resmetirom）是一种用于治疗非酒精性脂肪性肝炎(NASH) 的实验性药物。[1][2]它是甲状腺激素受体-β的选择性激动剂，可增加肝脏脂肪代谢并降低身体中过量脂肪的毒性。 [1]
参考文献
- ^ 1.0 1.1 Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. November 2019, 394 (10213): 2012–2024. PMID 31727409. S2CID 207976212. doi:10.1016/S0140-6736(19)32517-6.
- ^ Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape. Yahoo! Finance. January 23, 2023 [2023-05-15]. （原始内容存档于2023-02-07）.
- ^ Harrison SA. A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients with Well-Compensated NASH Cirrhosis. AASLD: The Liver Meeting. [2023-05-15]. （原始内容存档于2023-05-27）.
- ^ Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis (新闻稿). Madrigal Pharmaceuticals. December 19, 2022 [2023-05-15]. （原始内容存档于2023-12-16）.